Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 1
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 3(2)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06476704Phase 2Not Yet Recruiting

Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas

Role: collaborator

NCT06640777Phase 3Not Yet Recruiting

Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome

Role: lead

NCT06477939Phase 3Not Yet Recruiting

Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients

Role: collaborator

NCT04378920Phase 1Completed

A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes

Role: collaborator

All 4 trials loaded